CurifyLabs, a health technology company transforming how personalized medicines are made, secures $14 million in a Series A funding round. The round was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investors, including Lifeline Ventures. U.S. customers and employees also participated in the round.
The new capital will serve to expand U.S. operations, strengthen supply chain infrastructure, enhance customer support, and accelerate product innovation. It will specifically support ongoing development of the CurifyLabs platform, including its most recent product, the PharmaPrinter Aurum, which compounds up to nine times faster than manual processes.
As a reminder, the company founded in 2021 is acknowledged for its Compounding System Solution (CSS) which combines proprietary software, GMP-manufactured excipient bases, and advanced 3D printing technology to automate the preparation of personalized medications. With advanced quality control processes built in, the CSS produces tailored doses and dosage forms with greater precision and speed than the manual processes typically used in pharmacies today.
Pharmacies in 21 U.S. states and across Europe use CurifyLabs technology to compound and dispense thousands of doses every day. As the company continues to scale, it will invest in its supply chain to ensure its growing network of pharmacy partners has what it needs, when it needs it.
“This investment reflects the conviction our partners have in what we’re building,” said Charlotta Topelius, CEO and Founder, CurifyLabs. “We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.”
CurifyLabs’ technology is ISO 13485 certified and designed in compliance with FDA 503A/503B standards for non-sterile compounding.
*We curate insights that matter to help you grow in your AM journey. Receive them once a week, straight to your inbox. Subscribe to our weekly newsletter
